RESUMO
Breast cancer in men is a rare pathology. The most common clinical presentation is a palpable and painless retroareolar nodule. In men, it is a rare pathology, there are few studies on the matter, where breast cancer trials frequently exclude men. Objective: to present the incidence of breast cancer in men from the "Regional Hospital of Talca" Method: Retrospective and descriptive study of cases of breast cancer in men who have been treated and followed up in the Breast Pathology Unit of the Regional Hospital of Talca from January 1, 2011 to December 31, 2021.Results: There were 9 cases of breast cancer in men. Average age at diagnosis was 63 years, all patients were 50 years of age or older. One hundred percent of patients consulted for a self-palpable breast nodule. Average size on physical examination was 30 mm. The most frequent histology was invasive ductal carcinoma (56%), followed by invasive tubular carcinoma (22%) and ductal carcinoma in situ (11%). Immunohistochemistry was 100% positive for estrogen and progesterone receptor. Surgery in 56% of cases was total mastectomy with axillary dissection, and in 33% it was total mastectomy alone. 4 patients underwent adjuvant treatment with chemotherapy, and just one required a combination of chemotherapy and radiotherapy. During follow-up, only 2 patients died. Conclusion. Breast cancer in men is not very prevalent and the management is extrapolated from large studies in women, we believe that it is essential to have studies in male patients, to really have clarity on the behavior and evolution of the disease.
Assuntos
Humanos , Masculino , Pessoa de Meia-Idade , Idoso , Carcinoma Ductal de Mama/terapia , Neoplasias da Mama Masculina/terapia , Mastectomia/métodos , Estudos Retrospectivos , Carcinoma Ductal de Mama/patologia , Carcinoma Ductal de Mama/epidemiologia , Terapia Combinada , Neoplasias da Mama Masculina/patologia , Neoplasias da Mama Masculina/epidemiologia , HistologiaRESUMO
Introducción. El cáncer de mama es la tercera causa de muerte en mujeres peruanas, siendo una enfermedad genéticamente heterogénea, no existen estudios sobre el comportamiento del marcador de proliferación celular Ki-67 en esta población. Objetivo. Analizar la asociación entre las características clínico patológicas del cáncer de mama y la expresión del marcador celular Ki-67 en el Hospital Nacional Edgardo Rebagliati Martins (HNERM), Lima-Perú. Métodos. Estudio retrospectivo, realizado con las muestras diagnósticas de 209 pacientes con cáncer de mama. Las características clínico patológicas evaluadas fueron: edad, tipo histológico, tamaño tumoral, grado histológico, invasión linfovascular, ganglio linfático axilar, estadío clínico según el TNMp, receptor estrógenos (RE), receptor de progesterona (RP), y los inmunofenotipos Her2+, triple positivo (TP) y triple negativo (TN). La expresión del marcador celular Ki-67 fue categorizado como bajo (Ki-67<20%) y alto (Ki-67>20%). Resultados. La expresión alta del marcador celular Ki-67 se asoció con tumores de 2 cm, grado histológico 2 y 3, mayor número de ganglios axilares afectados y los inmunofenotipos Her2+ y triple negativo. La expresión baja del Ki-67 (<20%) se asoció con los tumores estrógeno y progesterona positivo. Conclusión. El marcador celular Ki-67 con expresión alta (>20%) mostró asociación significativa con características tumorales de mal pronóstico conocidas en cáncer de mama.
Introduction. Breast cancer is the third cause of death in peruvian women, a genetically heterogeneous disease, there are no studies on the behavior of the Ki-67 cell proliferation marker in this population. Objective. To analyze the association between the clinical pathological characteristics of breast cancer and the expression of the Ki-67 antigen in Hospital Nacional Edgardo Rebagliati Martins (HNERM), Lima-Perú. Methods. A retrospective study conducted in diagnostic samples of 209 patients with breast cancer. The clinical pathological characteristics were: age, histological type, tumor size, histological grade, lymphovascular invasion, axillary lymph node, clinical stage (TNMp), RE, RP, Her2+, triple positive, triple negative. The Ki-67 cell marker expression was categorized as low (Ki-67<20%) and high (Ki-67>20%). Results. High expression of the Ki-67 cell marker (>20%) was associated with tumors of 2cm, histological grade 2 and 3, greater number of axillary ganglia affected and Her2+ and triple negative inmunophenotypes. Low expression of Ki-67 (<20%) was associated with estrogen and progesterone positive tumors. Conclusion. The Ki-67 cell marker with high expression (>20%) shows a significant association with characteristics of poor prognosis well known in breast cancer.